Introduction
============

Thyroid cancer is one of the malignancies whose incidence is rapidly increasing in the world, and the incidence rate reached 13.5 per 100,000 in 2008.[@b1-ott-11-1345],[@b2-ott-11-1345] Papillary thyroid carcinoma (PTC) originating from thyroid epithelial cells is the most frequent type of thyroid cancer, accounting for about 80% of all thyroid cancers.[@b3-ott-11-1345] Currently, operative treatment and hormonotherapy are the main therapies for PTC with favorable prognosis.[@b1-ott-11-1345],[@b4-ott-11-1345] However, metastasis of PTC to lymphatic vessels remains a severe problem in the clinical treatment of PTC. Previous studies have demonstrated that the clinical outcome of metastatic PTC was affected by several prognostic factors including histologic type, tumor size, tumor infiltration, and vascular or lymphatic invasion, among which genetic factors were found to be the main reason for the development of PTC.[@b4-ott-11-1345]

Interleukin-13 receptor α2 (IL13Rα2) has high affinity to Th2-derived cytokine IL-13. Because of the short cytoplasmic domain, IL13Rα2 has previously been regarded as a decoy receptor to inhibit IL-13-mediated JAK--STAT6 activation.[@b5-ott-11-1345] Subsequent research suggests that binding of IL13Rα2 to IL-13 induces TGF-β1 through the AP-1 complex.[@b6-ott-11-1345] The elevated expression of IL13Rα2 has been observed in several human tumors, such as in prostate, kidney, and pancreatic cancer.[@b7-ott-11-1345]--[@b12-ott-11-1345] IL13Rα2 is shown to promote the invasion and metastasis of pancreatic, colon, ovarian, and breast cancer.[@b8-ott-11-1345],[@b13-ott-11-1345]--[@b15-ott-11-1345] Patients with benign or malignant thyroid disease had significantly higher serum levels of IL-13 as compared to healthy controls.[@b16-ott-11-1345] Vascular endothelial growth factor (VEGF) is overexpressed in PTC, and its expression is associated with the incidence of metastasis.[@b17-ott-11-1345] VEGF is stimulated by IL-13 and then mediates the protective effects of IL-13 on hyperoxic acute lung injury.[@b18-ott-11-1345] However, there are no studies comparing the expression of IL13Rα2 between PTC tissues and paracancerous tissues, as well as investigating the contribution of IL13Rα2 to papillary thyroid carcinogenesis. In addition, the association between VEGF and IL13Rα2 in PTC has not been documented.

In the present study, expression levels of IL13Rα2 and VEGF in PTC tissues and paracancerous tissues were measured. Besides, cell proliferation, apoptosis rate, and invasion ability were evaluated in two PTC cell lines after IL13Rα2 knockdown. Furthermore, Western blot was employed to measure the signaling pathway proteins. The results suggest that IL13Rα2 may function as an oncogene during papillary thyroid carcinogenesis.

Materials and methods
=====================

Tissue samples
--------------

The study protocol was approved by the local independent ethical committee of Shanghai Gongli Hospital (IE14013, date: September 4, 2014) and was performed according to the ethics committee's guidelines. PTC tissue samples and paired paracancerous tissues were obtained from 45 patients after all the participants had given written informed consent.

Real-time polymerase chain reaction (PCR) analysis
--------------------------------------------------

Total RNA was isolated from tissue samples or cultured cell lines by using Trizol Reagent (Invitrogen; Thermo Fisher Scientific). cDNA was synthesized by using a reverse transcription kit (Fermentas, Shanghai, People's Republic of China) and Oligo(dt)~18~. Then real-time PCR was conducted by using SYBR Green PCR kit (Thermo Fisher Scientific, Waltham, MA, USA) on the ABI 7300 Real-Time PCR System (Applied Biosystems, Waltham, MA, USA) with the following primers: IL13Rα2, 5′ GCATTGAAGCGAAGATACAC 3′ and 5′ ACGCAATCCATATCCTGAAC 3′; VEGF, 5′ ATTTCTGGGATTCCTGTAG 3′ and 5′ CAGTGAAGACACCAATAAC 3′; glyceraldehyde-3-phosphate dehydrogenase (GAPDH), 5′ CACCCACTCCTCCACCTTTG 3′ and 5′ CCACCACCCTGTTGCTGTAG 3′. The PCR conditions were as follows: 10 minutes at 95°C, and then 40 cycles of 15 seconds at 95°C, and 45 seconds at 60°C. Data were collected and analyzed using ABI Prism 7300 SDS Software (Applied Biosystems; Thermo Fisher Scientific).

Immunohistochemistry analysis
-----------------------------

After fixation in 10% formalin for 48 hours, the tissue samples were processed with histological embedding techniques and cut into 4 µm-thick sections. The slides were deparaffinized in xylene and rehydrated in graded alcohols. For antigen retrieval, the sections were autoclaved using a high-pressure method for 15 minutes in a commercially available 0.01 M sodium citrate solution (pH 6.0). Subsequently, the slides were incubated with 3% hydrogen peroxide in phosphate-buffered saline (PBS, pH 7.4) for 10 minutes to quench endogenous peroxidases. Slides were then probed with the primary antibody against IL13Rα2 (Abcam, Cambridge, UK) or VEGF (Abcam) for 1 hour at room temperature, followed by horseradish peroxidase-labeled secondary antibody for another 30 minutes at room temperature. After the antibody--antigen reaction, chromogen diaminobenzidine was applied to the slides. Finally, the sections were counterstained with 10% Harris hematoxylin, dehydrated, and mounted.

Cell culture and transfection
-----------------------------

PTC cell lines, TPC-1 and ARO, were obtained from the Chinese Academy of Sciences (Shanghai, People's Republic of China) and cultured in Dulbecco's Minimum Essential Medium (DMEM) containing 10% fetal calf serum (FCS) and antibiotics in a humidified atmosphere with 5% CO~2~ at 37°C. Cells were digested with trypsin and seeded into a six-well plate (5×10^5^ cells/well) before transfection. Lipofectamine™ 2000 (Invitrogen) was used to transfect IL13Rα2 siRNAs (siRNA-1, GGCUAUCGGAUGCUUAUAU); siRNA-2 (CAGGAUAUGGAUUGCGUAU) or negative control siRNA (NC) into PTC cells. At 48 hours posttransfection, cells were collected and evaluated for knockdown effect by using real-time PCR and Western blot assay. Then, transfected TPC-1 and ARO cells were processed for Cell Counting Kit-8 (CCK-8), flow cytometry, Transwell, biochemistry, Western blot, and real-time PCR analyses.

Western blot assay
------------------

Western blot assay was employed to determine the IL13Rα2 and related proteins' expression level in PTC cell lines. Cells were washed twice with ice-cold PBS followed by incubation with the RIPA lysis buffer (Beyotime, Haimen, People's Republic of China) at 4°C. The extracted protein was collected by centrifugation at 12,000 rpm for 15 minutes at 4°C. Protein concentrations were determined by using bicinchoninic acid method (Thermo Fisher Scientific). Equal amounts of protein from each sample were loaded on 10% sodium dodecylsulphate--polyacrylamide gels. After electrophoresis, proteins on the gel were transferred onto a nitrocellulose blotting membrane (Millipore, Billerica, MA, USA) and incubated with 5% skim milk in Tris-buffered saline Tween 20 at 4°C for 1 hour. The membranes were then incubated with antibodies against IL13Rα2 (Abcam), VEGF (Abcam), VEGFR2 (Affinity, Cincinnati, OH, USA), MMP2 (Abcam), MMP9 (Abcam), cleaved Caspase 3 (Abcam), cleaved poly (ADP)-ribose polymerase (PARP), or GAPDH (Cell Signaling Technology, Danvers, MA, USA) for 2 hours at room temperature. Then the membrane was washed three times with Tris-buffered saline and incubated with horseradish peroxidase-conjugated secondary antibodies (Beyotime) for 1 hour. Immunoreactive bands were detected using an ECL detection kit (Millipore). The densities of the bands were semi-quantified using ImageJ software.

CCK-8 assay
-----------

Cultured PTC cells were trypsinized, plated into 96-well plates (2×10^3^ cells/well), and incubated at 37°C overnight. The cells were then transfected with siRNA-1, siRNA-2, or NC. At 0, 24, 48, and 72 hours posttransfection, 100 µL DMEM containing 10% CCK-8 (Dojindo Biochem., Kumamoto, Japan) was added to each well, and then incubated in 5% CO~2~ at 37°C for 1 hour. The OD~450\ nm~ was measured using a spectrophotometer to evaluate cell proliferation.

Flow cytometry
--------------

At 48 hours after transfection, cells were collected, washed with PBS, and centrifuged at 1,000 rpm for 5 minutes. The pelleted cells were then labeled with Annexin V fluorescein isothiocyanate apoptosis detection kit (BD Biosciences, Franklin Lakes, NJ, USA) at room temperature for 20 minutes in the dark. Cell apoptosis rate was evaluated using a flow cytometer (FACS Calibur, BD Biosciences).

Transwell analysis
------------------

Transfected cells were starved in serum-free DMEM overnight, trypsinized, and diluted to 3×10^5^ cells/mL in DMEM containing 1% FCS. Cell suspension at a volume of 0.3 mL was added into the upper chamber precoated with matrigel, and 0.75 mL DMEM containing 10% FCS was added into the lower chamber. After the incubation for 48 hours, the cells remaining in the upper surface were carefully removed. The invaded cells were fixed by formalin for 10 minutes, stained with 0.5% crystal violet for 30 minutes, and counted in three randomly selected visual fields under a microscope (OLYMPUS, Shenzhen, People's Republic of China) at ×200 magnification.

Biochemical test
----------------

The activities of Caspase 3 and Caspase 9 were assessed using Caspase 3 and Caspase 9 colorimetric assay kits (Keygen Biotech Ltd., Nanjing, People's Republic of China) following the manufacturer's protocols. Cultured and transfected cells were collected and washed twice with PBS, followed by lysis with 100 µL precooled lysis buffer. The supernatant was collected by centrifugation at 10,000 rpm for 1 minute. Protein concentrations were determined using the bicinchoninic acid method. An equal volume of supernatant and 2× reaction buffer were mixed in a tube, and 5 µL of Caspase 3 or Caspase 9 substrate was added. After 4 hours of incubation at 37°C, the activity of Caspase 3 and Caspase 9 was measured at OD~400\ nm~.

Statistical analysis
--------------------

GraphPad Prism software (GraphPad Software, Inc., La Jolla, CA, USA) was used for data analysis. Student's *t*-test was used to analyze the differences of IL13Rα2 and VEGF expression between PTC and paracancerous tissues. Pear-son's correlation test was applied to determine the existence of a relation between IL13Rα2 and VEGF expression in PTC tissues. One-way analysis of variance followed by Tukey's post hoc test was performed for multiple comparison. A *P*-value \<0.05 was defined as statistically significant.

Results
=======

Higher expression levels of IL13Rα2 and VEGF were detected in PTC tissues
-------------------------------------------------------------------------

Real-time PCR was employed to evaluate the IL13Rα2 and VEGF expression in 45 pairs of PTC tissues and paracancerous tissues. As the results illustrate in [Figure 1A and B](#f1-ott-11-1345){ref-type="fig"}, higher mRNA levels of IL13Rα2 and VEGF were measured in PTC tissues in comparison to those in paracancerous tissues, with significant differences (*P*\<0.01), indicating the overexpression of IL13Rα2 and VEGF in PTC tissues. In addition, Pearson's correlation analysis indicated that IL13Rα2 mRNA level in the tested PTC tissues was significantly positively correlated with VEGF mRNA level (*P*\<0.0001) ([Figure 1C](#f1-ott-11-1345){ref-type="fig"}). Subsequently, immunohistochemistry analysis was performed, and higher protein levels of IL13Rα2 and VEGF were also observed in PTC tissues compared with paracancerous tissues ([Figure 1D and E](#f1-ott-11-1345){ref-type="fig"}).

Knockdown of IL13Rα2 inhibited cell proliferation in PTC cells
--------------------------------------------------------------

To further investigate the role of IL13Rα2 in PTC, we knocked down IL13Rα2 through siRNA transfection. In order to identify the interference effect, the expression of IL13Rα2 in PTC cell lines, TPC-1 and ARO, transfected with IL13Rα2 siRNAs (siRNA-1 or siRNA-2) was measured through Western blot and real-time analyses. As shown in [Figure 2A and B](#f2-ott-11-1345){ref-type="fig"}, siRNA-transfected PTC cells exhibited significantly decreased mRNA and protein expression of IL13Rα2 compared with NC-transfected cells and control cells (*P*\<0.001), indicating the efficient gene silencing of IL13Rα2 siRNAs. Subsequently, cell proliferation of TPC-1 and ARO cells with IL13Rα2 silenced was evaluated by using CCK-8. As shown in [Figure 2C](#f2-ott-11-1345){ref-type="fig"}, cell proliferation of PTC cells as detected by using CCK-8 was significantly reduced at 24, 48, and 72 hours after the treatment with IL13Rα2 siRNAs in comparison to NC group and control group, indicating the inhibition effect of IL13Rα2 siRNAs on cell proliferation of PTC cells.

IL13Rα2 siRNA induced cell apoptosis
------------------------------------

Annexin V/propidium iodide staining followed by flow cytometry analysis was then applied to detect cell apoptosis. The lower right quadrant of the histograms presents the early apoptotic cells. [Figure 3A](#f3-ott-11-1345){ref-type="fig"} shows a significantly induced cell apoptosis in IL13Rα2 siRNA groups (siRNA-1 and siRNA-2) in comparison to NC group and control group (*P*\<0.001). Further, the activity of proapoptotic proteins Caspase 3 and Caspase 9 measured by using biochemical analysis demonstrated upregulation after the treatment with IL13Rα2 siRNA ([Figure 3B](#f3-ott-11-1345){ref-type="fig"}). The expression of cleaved Caspase 3 and PARP was upregulated in IL13Rα2 siRNA groups (siRNA-1 and siRNA-2) as compared to control groups ([Figure 3C](#f3-ott-11-1345){ref-type="fig"}). These findings further indicated the proapoptotic ability of IL13Rα2 siRNA.

IL13Rα2 siRNA inhibited cell invasion
-------------------------------------

Besides, Transwell assay was performed to evaluate the invasive capacity of TPC-1 and ARO cells. As the result shows in [Figure 4A](#f4-ott-11-1345){ref-type="fig"}, the invasion capacity of TPC-1 cells treated with IL13Rα2 siRNAs (siRNA-1 and siRNA-2) was suppressed dramatically compared with the NC and control group (*P*\<0.001).

Knockdown of IL13Rα2 changed the expression of metastasis- and angiogenesis-related proteins
--------------------------------------------------------------------------------------------

To further investigate the possible mechanisms involved in the functions of IL13Rα2 siRNA, the expression levels of VEGF, VEGFR2, MMP2, and MMP9 in TPC-1 and ARO cells were measured by Western blot. Compared with control group, expression levels of VEGF, VEGFR2, MMP2, and MMP9 exhibited downregulation with a significant difference in PTC cells transfected with IL13Rα2 siRNA ([Figure 4B](#f4-ott-11-1345){ref-type="fig"}, *P*\<0.001).

Discussion
==========

In the present study, the overexpression of IL13Rα2 in PTC was demonstrated, which has been reported in other malignancies,[@b7-ott-11-1345]--[@b11-ott-11-1345] and the overexpression of VEGF in PTC tissues was confirmed. Additionally, a positive correlation between IL13Rα2 and VEGF expression was observed in PTC tissues. Further, the possible role of IL13Rα2 in the progress of PTC was investigated through knockdown of the receptor. As the results obtained in this study show, inhibited cell proliferation, induced cell apoptosis rate, and suppressed cell invasion in IL13Rα2 silenced cells suggest that IL13Rα2 may function as an oncogene in PTC.

Consistent with the previous report that IL13Rα2 knockdown could induce apoptosis of glioma cells,[@b19-ott-11-1345] the results of flow cytometry analysis showed a significant increase in apoptosis rate of TPC-1 and ARO cells after the treatment with IL13Rα2 siRNA. Caspases are critical mediators of cell apoptosis. During programmed cell death, Caspase 9, an initial Caspase, is activated and then activates downstream Caspases, such as Caspase 3 and Caspase 7.[@b20-ott-11-1345] Activated Caspase 3 induces the cleavage of downstream substrates, including PARP,[@b21-ott-11-1345] and the release of Caspase-activated deoxyribonuclease, leading to the prevention of DNA repair cycles, the degradation of DNA, instability of chromatin, and ultimately the apoptosis of cells.[@b22-ott-11-1345]--[@b24-ott-11-1345] Here, upregulated Caspase 3 and Caspase 9 activity and elevated cleavage of Caspase 3 and PARP were detected in PTC cells with IL13Rα2 silenced. Our study demonstrated that the increased apoptosis caused by depletion of IL13Rα2 was involved in the upregulated activity of Caspase 3.

Infiltrative growth and metastasis are the two most intractable characteristics of PTC that contribute to the poor prognosis of PTC.[@b2-ott-11-1345]--[@b4-ott-11-1345] Consistent with the previous report in glioma cells,[@b25-ott-11-1345] our results showed a significant reduction in the growth and invasion of TPC-1 and ARO cells after the treatment with IL13Rα2 siRNA. Epithelial--mesenchymal transition and mesenchymal--epithelial transition are essential for tumor metastasis. The basement membrane is mostly composed of Type IV collagen which is degraded by MMP family proteins MMP2 and MMP9. The basement membrane maintains tissue organization, provides structural support to the cells, and influences cell signaling and polarity.[@b26-ott-11-1345] Mesenchymal--epithelial transition accompanied by the degradation of basement membrane promotes epithelial--mesenchymal transition, which is an essential step for the metastatic progression in most cancers.[@b27-ott-11-1345] Besides, tumor angiogenesis factors involved in generation of tumor blood vessels play a crucial role in tumor metastasis, resulting in the uncontrolled growth of tumor. Angiogenesis during mesenchymal--epithelial transition is a complicated process regulated by several positive and negative regulatory factors.[@b28-ott-11-1345],[@b29-ott-11-1345] It has been demonstrated that VEGF as a specific heparin-binding growth factor in vascular endothelial cells can induce angiogenesis through the recruitment of tumor-associated macrophages, which participate actively in the angiogenesis and growth of tumors.[@b30-ott-11-1345] In this study, the number of invading cells declined significantly after the knockdown of IL13Rα2 in comparison to NC, suggesting that IL13Rα2 is involved in the invasion of PTC cells. Correspondingly, downregulation of MMP2, MMP9, VEGF, and VEGFR2 was observed in PTC cells after transfection with IL13Rα2 siRNA. All these findings suggested the inhibition ability of IL13Rα2 siRNA in tumor metastasis of PTC.

Conclusion
==========

Overall, it was demonstrated that IL13Rα2 and VEGF are upregulated in PTC. IL13Rα2 knockdown in PTC cells resulted in inhibited cell proliferation, induced cell apoptosis, and suppressed cell invasion. IL13Rα2 knockdown also suppressed the activity of Caspase 3 and Caspase 9, and reduced the expression of VEGF, VEGFR2, MMP2, and MMP9. Thus, these results suggest that IL13Rα2 may be a novel therapeutic target in the treatment of PTC, clinically.
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![Higher expression level of IL13Rα2 and VEGF were detected in PTC tissues.\
**Notes:** Higher mRNA levels of IL13Rα2 (**A**) and VEGF (**B**) were measured in PTC tissue samples (n=45) by using real-time PCR compared with paracancerous tissues (n=45). \*\**P*\<0.01, compared with paracancerous tissues. (**C**) Pearson's correlation analysis between IL13Rα2 and VEGF mRNA expression in PTC tissues (n=45). Protein levels of IL13Rα2 (**D**) and VEGF (**E**) in PTC and paracancerous tissues were evaluated by using immunohistochemistry analysis. Smaller staining areas of IL13Rα2 and VEGF were observed in paracancerous tissues, indicating the overexpression of IL13Rα2 and VEGF in PTC tissues.\
**Abbreviations:** IL13Rα2, interleukin-13 receptor α2; PCR, polymerase chain reaction; PTC, papillary thyroid carcinoma; VEGF, vascular endothelial growth factor.](ott-11-1345Fig1){#f1-ott-11-1345}

![Knockdown of IL13Rα2 inhibited cell proliferation.\
**Notes:** (**A**) The mRNA expression level of IL13Rα2 was measured by using real-time PCR in TPC-1 and ARO cells with IL13Rα2 siRNA transfection (siRNA-1 or siRNA-2). (**B**) The IL13Rα2 protein expression was measured by Western blot in TPC-1 and ARO cells after the transfection with IL13Rα2 siRNAs (siRNA-1 and siRNA-2). (**C**) IL13Rα2 siRNA inhibited cell proliferation in TPC-1 and ARO cells. \*\**P*\<0.01, \*\*\**P*\<0.001, compared with the NC group. ^\#\#^*P*\<0.01, ^\#\#\#^*P*\<0.001, compared with the NC group (n=3).\
**Abbreviations:** IL13Rα2, interleukin-13 receptor α2; NC, negative control siRNA; PCR, polymerase chain reaction.](ott-11-1345Fig2){#f2-ott-11-1345}

![Knockdown of IL13Rα2 induced cell apoptosis in PTC cells.\
**Notes:** (**A**) TPC-1 and ARO cells with IL13Rα2 knocked down showed a significant increase in apoptosis rate. (**B**) Increased activity of Caspase 3 and Caspase 9 were detected in TPC-1 and ARO cells after the knockdown of IL13Rα2. (**C**) The expression of cleaved Caspase 3 and PARP was determined by Western blot. \*\*\**P*\<0.001, compared with the NC group. ^\#\#\#^*P*\<0.001, compared with the NC group (n=3).\
**Abbreviations:** GAPDH, glyceraldehyde-3-phosphate dehydrogenase; IL13Rα2, interleukin-13 receptor α2; NC, negative control siRNA; PARP, poly (ADP)-ribose polymerase; PTC, papillary thyroid carcinoma.](ott-11-1345Fig3){#f3-ott-11-1345}

![IL13Rα2 siRNA inhibited cell invasion in TPC-1 cells.\
**Notes:** (**A**) Downregulation of invasion rate was detected in TPC-1 and ARO cells after the transfection with IL13Rα2 siRNAs (siRNA-1 and siRNA-2). (**B**) Expression levels of VEGF, VEGFR2, MMP2, and MMP9 in TPC-1 and ARO cells were measured by using Western blot analysis. \*\**P*\<0.01, \*\*\**P*\<0.001, compared with the NC group. ^\#\#^*P*\<0.01, ^\#\#\#^*P*\<0.001, compared with the NC group (n=3).\
**Abbreviations:** GAPDH, glyceraldehyde-3-phosphate dehydrogenase; IL13Rα2, interleukin-13 receptor α2; MMP2, matrix metallopeptidase 2; MMP9, matrix metallopeptidase 9; NC, negative control siRNA; VEGF, vascular endothelial growth factor; VEGFR2, VEGF receptor 2.](ott-11-1345Fig4){#f4-ott-11-1345}
